DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

GlobeNewswire Inc. • Dec 26, 2025 4:56pm (New York) •By Levi & Korsinsky, Llp

DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

DexCom faces a class action securities lawsuit alleging the company made unauthorized design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The complaint claims defendants overstated the devices' enhancements and concealed the true scope of issues, exposing the company to regulatory scrutiny and significant financial harm. Investors who suffered losses between January 8, 2024 and September 17, 2025 can join the lawsuit.

← Back to news Read Original Article

Insights

DXCM negative

The company faces serious allegations of securities fraud, unauthorized product design changes, FDA violations, and concealment of health risks associated with its medical devices. These factors pose significant legal, regulatory, and reputational risks that negatively impact investor confidence and shareholder value.

Keywords

#securities fraud #class action lawsuit #glucose monitoring devices #FDA violations #product reliability #investor losses

Tickers

DXCM

← Prev: You Don’t Need Big Money for These 3 Under-$30 Stock Plays

Next: StubHub Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – STUB →